Barinthus Biotherapeutics plc - American Depositary Shares — Cash Flow (NASDAQ:BRNS)

Financials

Cash from operating activities 32.58 M14.43 M50.92 M28.94 M 30.65 M Cash from investing activities 12.91 M5.75 M5.41 M892 K 692 K Cash from financing activities 222.74 M325 K1.87 M2.16 M 839 K Free cash flow 31.44 M8.29 M45.51 M28.05 M 30.34 M

Barinthus Biotherapeutics plc - American Depositary Shares

Barinthus Biotherapeutics plc is a biotechnology company developing immunotherapies for infectious diseases, cancer and autoimmune diseases such as hepatitis B, HPV and prostate cancer. Formerly known as Vaccitech plc, in November 2023 the company announced that it had renamed itself to Barinthus Biotherapeutics plc. As of 2024, the company employs more than 100 people.

BRNS

Financials

Barinthus Biotherapeutics plc - American Depositary Shares

Haberler

Barinthus Biotherapeutics PLC Sponsored ADR (BRNS) Upgraded to Buy: What Does It Mean for the Stock?

Barinthus Bio’nun çölyak tedavisi denemesinden olumlu ilk veriler geldi

Barinthus Bio reports positive initial data from celiac therapy trial

H.C. Wainwright, Barinthus Biotherapeutics için Al tavsiyesini yineledi

Barinthus Biotherapeutics stock rating reiterated at Buy by H.C. Wainwright

Barinthus Bio and Clywedog to merge in all-stock deal

Barinthus Biotherapeutics’ CEO Bill Enright to Present at the Investor Summit Virtual on June 10, 2025